News | December 28, 2021
CDSCO expert committee recommends Emergency Use Authorisation to Covovax and Corbevax
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
DCGI approved the drug based on the review of clinical data
The company has developed the API in house at its R&D center in Hyderabad
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
It plans to deliver over 300 million doses to the Indian government
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The company will market it under the brand name Molflu
The drug will be marketed under the brand name Molnaflu
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
Subscribe To Our Newsletter & Stay Updated
